Goldline Pharmaceutical IPO — Listing Performance
Goldline Pharmaceutical had a strong market debut, ending listing day 32.02% over the issue price, after the issue was subscribed an extraordinary 598.69 times.
Goldline Pharmaceutical IPO facts & figures
| Issue category | SME |
|---|---|
| Issue open date | 12-May-2026 |
| Listing date | 19-May-2026 |
| Issue size | ₹11.02 crore |
| Overall subscription | 598.69x |
| Issue price | ₹43 |
| Listing-day close | ₹56.77 (32.02%) |
| Recent market price | ₹42.29 (-1.65% vs issue) |
| 52-week range | ₹41.41 – ₹60 |
| Identifiers | BSE code: 544759 · ISIN: INE1CLW01015 |
Figures are compiled from public market data and refreshed when our dataset updates. Verify against BSE/NSE records before acting on them.
How the listing went
Goldline Pharmaceutical opened for subscription on 12-May-2026 as a SME issue raising about ₹11 crore. The shares were priced at ₹43 and made their debut on 19-May-2026, closing the first session at ₹56.77 — a listing-day change of 32.02%.
As of our last data refresh the stock trades around ₹42.29, 1.65% below the issue price. A listing-day gain does not guarantee lasting returns — and vice versa.
Every IPO in our archive gets this same treatment: real issue data, the actual listing-day result, and where the price stands now — so you can judge how debut hype translated into outcomes. Compare more debuts on the IPO listing-performance archive or check live grey-market sentiment on the GMP board.
Goldline Pharmaceutical IPO FAQs
What was the Goldline Pharmaceutical IPO listing price?
Goldline Pharmaceutical closed at ₹56.77 on its listing day (19-May-2026), against an issue price of ₹43 — a listing-day change of 32.02%.
How many times was the Goldline Pharmaceutical IPO subscribed?
The issue was subscribed about 598.69 times overall.
Was the Goldline Pharmaceutical IPO profitable for allottees?
On listing day, yes: allottees who sold at the closing price made about 32.02% over the issue price. Longer-term outcomes depend on when shares were sold.